Solid dispersion of alectinib HCl: preclinical evaluation for improving bioavailability and establishing an IVIVC model
A stable ASD formulation of ALB-HCl was successfully developed with improved bioavailability. Developing an IVIVC model can act as a surrogate to predict <i>in-vivo</i> performance. The selection of formulation components in ASD shall be rationalized for bioavailability and stability before clinical evaluation.
Authors
- Bala Krishna Panigrahy
- Sumit Kumar Saha (ORCID: https://orcid.org/0000-0001-9769-1829)
- Kiran Dubey
- Ajinkya Jadhav (ORCID: https://orcid.org/0000-0002-7255-9271)
- Amita Joshi (ORCID: https://orcid.org/0000-0002-3298-7415)
- Romi Singh (ORCID: https://orcid.org/0009-0009-1520-0949)
- Varun Arya (ORCID: https://orcid.org/0000-0002-0901-5693)
- S. Kailash
Institutions
- Delhi Pharmaceutical Science and Research University (IN)
- Pharmaceutical Formulations (United States) (US)
- Institute Of Pesticides Formulation Technology (IN)
- Sun Pharma Advanced Research (India) (IN)
- National Institute of Pharmaceutical Education and Research (IN)
- BioHybrid Solutions (United States) (US)
- Sun Chemical (United States) (US)
Publication Details
- Journal
- Drug Development and Industrial Pharmacy
- Published
- 2024-12-31
- DOI
- https://doi.org/10.1080/03639045.2024.2447276
- Primary Topic
- Drug Solubulity and Delivery Systems
- Type
- article
- Field-Weighted Citation Impact
- 0.00